Siamak Daneshmand

Dec 8, 2024 | urologytimes.com | Siamak Daneshmand

In this video, Siamak Daneshmand, MD, highlights data on the safety and tolerability of TAR-200 monotherapy in patients with non–muscle-invasive bladder cancer (NMIBC), which were shared at the Society of Urologic Oncology 25th Annual Meeting in Dallas, Texas. Daneshmand is a professor of urology and director of clinical research at the Keck School of Medicine of the University of Southern California, Los Angeles,Video Transcript:Could you describe the background/design of the SunRISe-1 trial?

Sep 30, 2024 | europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.

May 15, 2024 | urotoday.com | Siamak Daneshmand

Read the Full Video TranscriptPat Hensley: Hi, my name is Pat Hensley. I'm a urologic oncologist at the University of Kentucky College of Medicine, and I'd like to welcome you to today's Uro Today presentation and discussion on the role of pelvic lymphadenectomy during radical cystectomy for muscle invasive bladder cancer. I'd like to welcome our two distinguished guests and colleagues here today. First, Seth Lerner, who is a professor of urology at the Baylor College of Medicine in Houston, Texas.

May 1, 2024 | urotoday.com | Siamak Daneshmand

Read the Full Video TranscriptAshish Kamat: Hello, and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat, professor of urologic oncology at MD Anderson Cancer Center. It's a pleasure to welcome once again to this forum, someone who really needs no introduction, Professor Sia Daneshmand from USC. Sia, you've done a lot of work when it comes to enhanced cystoscopy, better detection of tumors, resection, surgical technique, etc.

Feb 7, 2024 | urotoday.com | Siamak Daneshmand

Sam Chang and Siamak (Sia) Daneshmand delve into the ABLE-41 trial, focusing on real-world usage of nadofaragene firadenovec for bladder cancer. Discussing the trial's design and objectives, they emphasize its significance in capturing diverse patient experiences and outcomes outside the confines of traditional clinical trials.